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Aberrant splicing and defective mRNA production
induced by somatic spliceosome mutations in
myelodysplasia
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Spliceosome mutations are frequently found in myelodysplasia. Splicing alterations induced
by these mutations, their precise targets, and the effect at the transcript level have not been
fully elucidated. Here we report transcriptomic analyses of 265 bone marrow samples from
myelodysplasia patients, followed by a validation using CRISPR/Cas9-mediated gene editing
and an assessment of nonsense-mediated decay susceptibility. Small but widespread
reduction of intron-retaining isoforms is the most frequent splicing alteration in SF3B1-
mutated samples. SF3B1 mutation is also associated with 3′ splice site alterations, leading to
the most pronounced reduction of canonical transcripts. Target genes include tumor sup-
pressors and genes of mitochondrial iron metabolism or heme biosynthesis. Alternative exon
usage is predominant in SRSF2- and U2AF1-mutated samples. Usage of an EZH2 cryptic exon
harboring a premature termination codon is increased in both SRSF2- and U2AF1-mutated
samples. Our study reveals a landscape of splicing alterations and precise targets of various
spliceosome mutations.
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Myelodysplastic syndromes (MDS) and related diseasesare a heterogeneous group of chronic myeloid neo-plasms characterized by ineffective hematopoiesis,
peripheral blood cytopenia, and an increased risk of progression
to acute myeloid leukemia1,2. Splicing factor (SF) mutations
represent a novel class of driver mutations in human cancers and
affect about 50 to 60% of patients with a myeloid neoplasm with
myelodysplasia3–8. Somatic mutations are frequently found in
genes controlling 3′ splicing, including SF3B1, SRSF2, and
U2AF16–8. SF mutations are implicated in the pathogenesis of
MDS most likely via abnormal RNA splicing. The mutations are
heterozygous and clustered in speciﬁc amino acid residues6–8.
These “hotspot” mutations are predicted by protein structure
modeling to alter the RNA-binding speciﬁcity of the SFs9–11. In
vitro studies using cell lines have shown that mutant SF3B1
promotes usage of alternative branch points, leading to cryptic 3′
splice site activation11–14. SRSF2 and U2AF1 mutations were also
shown in vitro to alter exon splicing patterns9,10,15,16. These
alternative splicing patterns were conﬁrmed in mouse models of
SF mutations as well as in primary human samples9,10,17–22.
Moreover, mouse models have shown that the mutations in
SF3B1, SRSF2, and U2AF1 cause myelodysplastic
phenotypes10,17–20.
Despite these advances, several questions remain unanswered.
First, target genes of abnormal RNA splicing have not been fully
elucidated. Speciﬁc alternative splicing events observed in human
cells were often absent in mouse models, in which binding site
sequences of mutant SFs are not always conserved19,20,23. This
highlights the importance of identifying precise targets of aber-
rant RNA splicing in human hematopoietic cells. A large genetic
study is required to determine the precise targets among
numerous alternative splicing events observed in myelodysplasia.
Second, transcriptional consequences of abnormal RNA splicing
have not been systematically assessed. While the function of
alternatively spliced isoforms is often difﬁcult to predict. a fra-
meshift or a premature termination codon (PTC) that is fre-
quently introduced by mutant-SF-associated mis-splicing events
is likely to have deleterious effects on gene function with a
reduction in their canonical transcripts10–12. In addition, previous
studies reported several aberrant isoforms that were degraded by
nonsense-mediated decay (NMD) as a quality-control mechanism
that eliminates transcripts harboring a PTC10–12. A reduction of
canonical transcripts due to mutant-SF-induced mis-splicing
events and their sensitivity to NMD have not been evaluated in a
comprehensive manner.
To address these questions, we perform a comprehensive
transcriptome analysis on a large cohort of patients with mye-
lodysplasia. Transcriptional consequences of aberrant splicing are
further assessed using NMD inhibition experiments. We identify
small but widespread reduction of intron-retaining isoforms in
SF3B1-mutated samples. Reduction of canonical transcripts is
most pronounced in genes with mutant SF3B1-associated aber-
rant 3′ splice site selection. Target genes include tumor sup-
pressors and genes of mitochondrial iron metabolism or heme
biosynthesis. We also reveal that SRSF2 and U2AF1 mutations
have a common target of splicing alterations: EZH2. This study
provides a landscape of abnormal splicing associated with dif-
ferent spliceosome mutations and their precise targets.
Results
Mis-splicing patterns associated with spliceosome mutations.
We studied 214 patients with myeloid neoplasms with myelo-
dysplasia followed at the Department of Hematology Oncology,
Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. Patient
characteristics are summarized in Supplementary Table 1. The
mutation status of 89 known or putative driver genes in myeloid
neoplasms (Supplementary Table 2) was evaluated by targeted-
capture sequencing with a mean coverage of 1009× (range
207–2306×), followed by validation using RNA sequencing or
amplicon sequencing. We identiﬁed 313 non-synonymous single-
nucleotide variants, 147 small insertion–deletions in the driver
genes, and 170 copy number abnormalities and/or allelic imbal-
ances (Supplementary Fig. 1). A total of 124 patients (58%) had
mutations in one or more SFs, including SF3B1 (n= 68 (32%)),
SRSF2 (n= 39 (18%)), U2AF1 (n= 14 (6.5%)), and ZRSR2 (n=
10 (4.7%)) (Fig. 1a).
RNA sequencing was performed on bone marrow mononuclear
cells (BMMNCs; n= 165) and CD34+ cells (n= 100) obtained
from 214 patients, of whom 51 were analyzed for both cell
fractions (Fig. 1a). The number of unique reads ranged from 31 to
118 million, with a mean of 64 million (Supplementary Fig. 2). We
identiﬁed 190,301 and 147,809 alternative splicing events in
BMMNCs and CD34+ cells, respectively; these events were
categorized as described in Fig. 1b. The relative expression of
alternatively spliced isoforms was estimated from a “percent
spliced in (PSI)” value, which reﬂects the fraction of reads showing
alternative splicing over total reads24,25. To identify alternative
splicing events associated with each spliceosome mutation, we
compared PSI values between patients with and without the
spliceosome mutations by the unequal variance t-test (Fig. 1c).
P-values were adjusted for multiple testing by controlling a false-
discovery rate q-value using the Benjamini–Hochberg method,
with cut-off q-values <0.01.
SF3B1 mutation was signiﬁcantly associated with 3831
alternative splicing events in either BMMNCs or CD34+ cells
(Fig. 1c). SF3B1 mutation was most frequently associated with
increased usage of alternative 3′ splice sites and decreased intron
retention (Fig. 1d). Many of the altered 3′ splice sites were
observed almost exclusively in the SF3B1-mutated samples; these
abnormalities were commonly observed in the samples with any
SF3B1 hotspot mutation and were barely detected in the controls
(Fig. 2a and Supplementary Fig. 3). Reduction of intron-retaining
isoforms in SF3B1-mutated samples was rather unexpected. A
substantial number of introns failed to be fully spliced out and
were retained in SF-unmutated samples (Fig. 2a). In the SF3B1-
mutated samples, a slight but signiﬁcant decrease was observed in
the relative abundance of many intron-retaining isoforms
(Fig. 2a). Compared to the constitutively spliced introns, the
affected introns were shorter in length (median (interquartile
range (IQR)), 0.41 (0.16–1.1) vs. 1.8 (0.58–5.8) kb; P < 0.001) and
had a higher GC content (median (IQR), 54% (44–62%) vs. 43%
(38–52%); P < 0.001; the Mann–Whitney U test; Supplementary
Fig. 4). No differences were found in sequences around 5′ and 3′
splice sites (Supplementary Fig. 5). We also conﬁrmed that the
proportion of sequencing reads mapped to all the intronic regions
was actually decreased in SF3B1-mutated samples (Supplemen-
tary Fig. 6). These results indicated that SF3B1 mutation was
characterized by usage of abnormal 3′ splice sites and small but
widespread reduction of intron retention.
SRSF2 mutation was associated with 2057 events in either the
BMMNC or CD34+ cell fraction (Fig. 1c). Substantially different
patterns of aberrant splicing were observed in SRSF2-mutated and
SF3B1-mutated patients. In contrast to SF3B1 mutation, altered
exon usage was the predominant alteration in SRSF2-mutated
samples, accounting for 50% (n= 1025) of all mutant SRSF2-
associated events (Figs. 1d and 2b). These alternative splicing
events were not speciﬁc to the SRSF2-mutated samples, but were
also observed in SF-unmutated samples, albeit less abundantly
than in SRSF2-mutated samples (Fig. 2b). Three samples from two
patients have both SF3B1 and SRSF2 mutations in the major clone
as inferred from the variant allele frequencies (Supplementary
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Fig. 1 Overview of a transcriptomic analysis of 265 bone marrow samples. a Sources of RNA and frequencies of SF mutations. A Venn diagram shows
sources of RNA. The pie charts below depict frequencies of SF mutations among 165 cases with BMMNCs and 100 cases with CD34+ cells. b Types of
alternative splicing events. Cassette exon means inclusion or skipping of an exon. c An overview of differential splicing analysis. Comparison of splice
junction usage between SF-mutated and non-mutated samples was performed for each cell fraction. Alternative splicing events associated with each SF
mutation with a q-value of <0.01 were regarded as differentially spliced. Venn diagrams show numbers of alternative splicing events signiﬁcantly
associated with each SF mutation. d Types and numbers of splicing alterations signiﬁcantly associated with each SF mutation. Bars in the upper half
indicate alternative splicing events that were more frequently found in SF-mutated cases. Bars in the lower half are those that were more frequently found
in the controls. Types of splicing alterations are color coded as in b
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Fig. 7). Both SF3B1- and SRSF2-associated alterations were
observed in these samples (Supplementary Fig. 8).
Similar to SRSF2 mutation, U2AF1 mutation was largely
associated with modest changes in exon usage. Of 126 alternative
splicing events that were associated with either of the two major
U2AF1 variants involving S34 or Q157, 110 (87%) were
alternative exon usage (Figs. 1d and 2c). Despite affecting the
same SF, there were no substantial overlap in abnormal spicing
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Fig. 2 Alternative splicing events associated with spliceosome mutations. a, b, c Scatter plots comparing mean PSI values between the SF3B1- (a), SRSF2-
(b), and U2AF1-mutated samples (c), and those without SF mutations. The number of samples in each group is shown in Fig. 1c. Signiﬁcantly associated
events (q-value <0.01) are color coded as in the bottom right panel. The panels in the right are scatter plots for each splicing pattern, also showing the
number of signiﬁcant events. Other types of alternative exon usage included mutually exclusive exons, alternative ﬁrst exon, and alternative last exon
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associated with these two hotspot mutants; only three of 126
U2AF1-associated alternative splicing events were affected by
both mutations (Supplementary Fig. 9). This represents a
difference with SF3B1 hotspot mutations, all of which were
associated with a similar set of abnormally spliced sites
(Supplementary Fig. 3).
Effect of concurrent mutations in epigenetic regulators. Epi-
genetic modiﬁcations are known to have a major impact on
alternative splicing26. We assessed the effect of mutations in
epigenetic regulators that co-occurred with SF3B1 or SRSF2
mutations. Alternative splicing patterns were compared between
each SF-mutated samples with and without co-mutations in
epigenetic modiﬁers including TET2, DNMT3A, IDH1/IDH2,
ASXL1, or EZH2 (Supplementary Table 3). Although some
mutations were mutually exclusive with SF mutations, a sufﬁcient
number of SF-mutated patients had concurrent mutations espe-
cially in TET2 (Supplementary Table 3). However, we did not ﬁnd
any signiﬁcant alterations in splicing patterns associated with co-
mutations in epigenetic regulators (q-values <0.1 by t-test). We
next focused on the effect of TET2 mutations in genes that were
known to be differentially methylated in TET2-mutated leuke-
mia27. Again, no difference was found between alternative spli-
cing patterns in SF-mutated samples with and without TET2
mutation (Supplementary Fig. 10).
Effects of splicing alterations at the transcript levels. In terms of
predicted proteins, alternative splicing events were classiﬁed into
ﬁve groups: (i) truncating alterations, (ii) non-truncating altera-
tions, (iii) alternative ﬁrst coding exons, (iv) alternative last
coding exons, and (v) alterations in non-coding regions. Trun-
cating alterations introduce a frameshift or a PTC into a tran-
script, while non-truncating alterations yield an in-frame isoform
with nucleotide deletion or insertion.
In accordance with previous reports, alternative 3′ splice sites
associated with SF3B1 mutation were clustered within 10–30 bp
upstream of canonical 3′ splice sites, resulting in a nucleotide
insertion at the authentic exon–exon junction (Supplementary
Fig. 11)11,19,28. Of 671 alternative 3′ splice sites signiﬁcantly
associated with mutant SF3B1, 373 (56%) yielded a truncated
isoform, while 192 (29%) were non-truncating events (Fig. 3a).
Many SRSF2 mutations were also associated with alternative exon
usage that resulted in truncated isoforms, explaining 428 of 1025
(42%)) alternative cassette exons associated with mutant SRSF2
(Fig. 3b).
Truncating splicing alterations are likely to have deleterious
effects on gene function with a reduction in their canonical
transcripts. To assess the effects of mutant-associated alternative
splicing, we compared gene expression in CD34+ cells from
patients with and without spliceosome mutations using the
generalized linear model likelihood ratio test. The expression level
of transcripts without truncating splicing alterations was
estimated based on their PSI values. Target genes of mutant
SF3B1-associated alternative 3′ splice sites showed a highly
consistent reduction in canonical transcripts; 145 of 290 (50%)
target genes expressed in CD34+ cells were signiﬁcantly down-
regulated (q-value <0.01, Fig. 3c). Conversely, 25 of 30 genes
(83%) most signiﬁcantly downregulated in SF3B1-mutated
samples (q-value <1 × 10−20) contained one or more aberrant
3′ splice sites related to mutant SF3B1 (Fig. 3c). None of the other
alterations associated with mutant SF3B1 or SRSF2 showed such a
strong correlation with gene expression (Fig. 3d, and Supple-
mentary Figs. 12 and 13).
Nonsense-mediated decay of aberrant transcripts. The marked
reduction of canonical transcripts suggests that mutant-
SF-associated splicing alterations represent the mechanism
underlying downregulation of target genes, particularly in cells
harboring mutated SF3B1. However, only a trace amount of
aberrant transcripts was detected for some downregulated genes
(Fig. 4a). We hypothesized that these aberrant transcripts were
normally transcribed but were degraded by NMD (Fig. 4a). To
test this hypothesis, we assessed whether the transcripts with
splicing alterations increased after inhibition of NMD by paired t-
test.
Primary bone marrow cells with mutated SF3B1 (n= 4) or
SRSF2 (n= 4), as well as those having no known SF mutations
(n= 2), were treated with cycloheximide (CHX) to inhibit NMD,
and were then subjected to RNA sequencing, together with
untreated cells. Effective inhibition was conﬁrmed by an increase
in the level of the physiological targets of NMD (Supplementary
Fig. 14). We identiﬁed 6591 alternative splicing events that were
speciﬁcally detected after CHX treatment, but not in the primary
samples. Such events are expected to represent complete
degradation by NMD under physiological conditions. However,
none of them were associated with either SF3B1 or SRSF2
mutation (P-value <0.05 by t-test) and it is unlikely that we had
failed to detect major targets of these mutations in the analysis of
the primary samples. We thus focused our analysis on already
identiﬁed splicing alterations. While CHX treatment did not
substantially inﬂuence the PSI values of non-truncating splicing
alterations, a signiﬁcant (q-value <0.01) increase in PSI values was
detected in 76 (3.9%) and 34 (5.2%) truncating events associated
with SF3B1 and SRSF2 mutations, respectively (Fig. 4b and
Supplementary Figs. 15 and 16). The most common targets of
NMD were transcripts with mutant SF3B1-associated alternative
3′ splice sites. A signiﬁcant increase after CHX treatment was
detected in 48 events (Fig. 4c), which were consistently associated
with a reduction in the corresponding canonical transcripts (Fig. 4d).
Transcripts with other splicing patterns were also degraded by
NMD (Supplementary Figs. 15 and 16), although the reduction in
the corresponding authentic transcripts was less prominent
compared to that in the targets of mutant SF3B1-associated
alternative 3′ splice sites (Supplementary Figs. 12 and 13).
Overall, these results suggest that the paucity of the aberrant
transcripts in some targets was a result of degradation by NMD,
indicating a larger effect of the splicing alterations on gene
expression than expected from the observed amounts of
abnormal transcripts in the primary samples (Fig. 4a).
Recapitulation of mutant SF3B1-associated abnormal splicing.
To test whether mutant SF3B1-associated splicing alterations
were solely attributable to SF3B1 mutation, we generated isogenic
cell lines carrying the SF3B1K700E mutation. Clustered regularly
interspaced short palindromic repeat (CRISPR)/CRISPR-asso-
ciated protein-9 (Cas9) nuclease technology was used to knock in
a heterozygous SF3B1K700E allele, where HEK293T cells were
chosen as target cells because of technical feasibility. A CRISPR/
Cas9-blocking synonymous mutation was also introduced to
obtain SF3B1 wild-type controls. We isolated six independent
CRISPR cell clones: three with a heterozygous SF3B1K700E
mutation and three with wild-type SF3B1 (Supplementary
Fig. 17).
PSI values of 3831 mutant SF3B1-associated alternative splicing
events were compared between the CRISPR cell lines with and
without the SF3B1K700E mutation (Supplementary Fig. 18). A
total of 909 events (24%) showed consistent changes with a
P-value <0.05 by t-test in clones with a heterozygous SF3B1K700E
allele (Fig. 5a). Increased usage of aberrant 3′ splice sites was most
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frequently recapitulated in SF3B1-mutated clones (599 of 671
events (89%), Fig. 5a, b). Many target genes of mutant SF3B1-
induced alternative 3′ splice sites again showed a reduction in
canonical transcripts (Supplementary Fig. 19). As in the primary
bone marrow samples, the relative expression of intron-retaining
isoforms showed modest differences in this isogenic model
(Fig. 5c); the CRISPR cell clones with the SF3B1K700E mutation
frequently showed decreased retention in 1279 introns of which
retention was reduced in SF3B1-mutated primary samples (Fig. 5c,
d). It was more consistent in 134 intron retention events with
highly signiﬁcant reduction in SF3B1-mutated primary samples
(q-value <1 × 10−5; Supplementary Fig. 20).
To investigate the intracellular localization of intron-retaining
transcripts, cytoplasmic, and nuclear RNA were separately
extracted from the CRISPR cell lines. The enrichment of nuclear
RNA was conﬁrmed by the ~40S precursor rRNA peaks in the
electropherogram and relative increase in small RNAs (Supple-
mentary Fig. 21). RT-PCR was performed for several intron-
retaining isoforms of which relative expression was decreased in
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Fig. 3 Transcriptional consequences of splicing alterations. a, b Types and numbers of splicing alterations signiﬁcantly associated with SF3B1 (a) and SRSF2
mutations (b). Bars in the right indicate alternative splicing events that were more frequently found in SF-mutated cases. Bars in the left are those that were
more frequently found in the controls. Colors indicate consequences of splicing alterations at the transcript level. c, d Volcano plots comparing expression
levels of the authentic transcripts between the SF3B1- (c) and SRSF2-mutated CD34+ cells (d) and those without known SF mutations. The number of
samples in each group is shown in Fig. 1c. X-axis indicates fold changes in gene expression on a log2 scale. Y-axis indicates q-values on a negative log10
scale. Target genes of mutant SF3B1-associated alternative 3′ splice sites are depicted in red (c). Those of mutant SRSF2-associated cassette exons are
depicted in blue (d)
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Fig. 4 Nonsense-mediated decay of aberrant transcripts and downregulation of target genes. a Relative expression of some target genes of mutant SF3B1-
associated alternative 3′ splice sites in the SF3B1-mutated CD34+ cells as compared with those without SF mutations. Blue bars indicate expression levels
of the authentic transcripts. Pink and red bars indicate those of the aberrant transcripts detected before and after CHX treatment, respectively. These genes
had a seemingly small amount of the aberrant transcripts that increased after CHX treatment. b, c Volcano plots comparing PSI values of SF3B1-associated
splicing alterations between samples with and without CHX treatment (n= 4 each). Alternative splicing events were separately plotted for non-truncating
events (b) and truncating ones (c). X-axis indicates fold changes in PSI values after CHX treatment on a log2 scale. Y-axis indicates P values on a negative
log10 scale. Transcripts increased after CHX treatment with a q-value <0.01 were regarded as sensitive to NMD. d A volcano plot comparing gene
expression levels between the SF3B1-mutated CD34+ cells (n= 32) and those without known SF mutations (n= 41). X-axis indicates fold changes in gene
expression on a log2 scale. Y-axis indicates q-values on a negative log10 scale. Target genes of mutant SF3B1-associated alternative 3′ splice sites and NMD
are depicted in red
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were detected not only in the nucleus, but also in the cytoplasm
(Fig. 6a), indicating that some intron-retaining transcripts were
normally exported to the cytoplasm. Expression levels of intron-
retaining isoforms relative to spliced ones were compared between
the CRISPR cell lines with and without the SF3B1K700E mutation.
Although intron retention was decreased in both the nucleus and
cytoplasm of SF3B1-mutated cells, the decrease was more
pronounced in the cytoplasm than in the nucleus (Fig. 6a). The
CRISPR cell lines were also treated with CHX to inhibit NMD,
which occurs in the cytoplasm. RT-PCR of cytoplasmic RNA
revealed that relative expression of intron-retaining transcripts did
not increase after CHX treatment (Fig. 6b). These results indicated
that a mutant SF3B1-associated decrease in intron retention was
not due to activated degradation of intron-retaining transcripts by
NMD, but was rather caused by enhanced splicing of retained
introns and/or impaired export of intron-retaining transcripts
from the nucleus of SF3B1-mutated cells (Fig. 6c).
The effect of transcriptional activity on abnormal splicing. We
have revealed that splicing alterations, especially those associated
with SF3B1 mutation, had a profound effect on gene expression
levels. Contrary to this, transcriptional activity might inﬂuence
the frequencies of alternative splicing events. To accurately assess
the effect of gene expression on abnormal splicing, we compared
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Fig. 5 Recapitulation of mutant SF3B1-associated abnormal splicing in vitro. a The number of mutant SF3B1-associated events that showed a consistently
signiﬁcant difference in CRISPR cell lines with the SF3B1K700E mutation. Bars on the right indicate alternative splicing events that were more frequently
found in SF3B1-mutated cell lines. Bars on the left represent those that were more frequently found in the controls. Red bars indicate events with consistent
changes with a P value <0.05 in CRISPR cell lines. b, c Scatter plots showing mean PSI values of mutant SF3B1-associated alternative 3′ splice sites (b) and
intron retention (c). The left and right panels show mean PSI values in primary bone marrow samples and in CRISPR cell lines, respectively. d A volcano plot
comparing mean PSI values of mutant SF3B1-associated intron retentions between CRISPR cell lines with and without the SF3B1K700E mutation (n= 3 each).
X-axis indicates fold changes in PSI values on a log2 scale. Y-axis indicates P values on a negative log10 scale
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Fig. 6 Decreased intron retention in SF3B1-mutated cells. a RT-PCR of several differentially spliced introns. RT-PCR was performed for total, nuclear, and
cytoplasmic RNA extracted from CRISPR cells with or without a heterozygous SF3B1K700E allele. Samples without reverse transcription (RT) were used as a
negative control. T indicates total RNA; N, nuclear RNA; C, cytoplasmic RNA. Relative amount of the intron-retaining isoforms that were calculated from
the intensity of bands are also shown on the right. b RT-PCR of several differentially spliced introns. RT-PCR was performed for cytoplasmic RNA with or
without CHX treatment. Relative amount of the intron-retaining isoforms that were calculated from the intensity of bands are also shown on the right. c A
schematic shows the amount of intron-retaining isoforms and spliced isoforms in the nucleus and the cytoplasm. The left panel is a schematic of SF3B1
wild-type cells, and the right is for SF3B1-mutated cells
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splicing alterations that fulﬁlled the following criteria: (i) events
almost speciﬁcally (>10-fold) detected in the SF-mutated samples;
(ii) mean PSI values >10%; (iii) non-truncating events that were
not sensitive to NMD. These criteria were met by 26 events, all of
which were mutant SF3B1-associated alternative 3′ splice sites. To
remove the effect of contaminating non-tumor cells, the analysis
was limited to 16 samples with SF3B1K700E allele that was
expressed in >90% of the cells as estimated from the variant allele
frequencies in RNA: nine bone marrow CD34+ cell samples, four
BMMNC samples, and three HEK293T cell lines with SF3B1K700E
mutation. As shown in Supplementary Fig. 22, no consistent
relationship was found between gene expression levels and PSI
values. Actually, a gene expression level was not a signiﬁcant
predictor of a PSI value (P= 0.09 by Wald test), when we
modeled the effect of gene expression levels using a generalized
linear model with a Gaussian distribution.
Target genes of mutant SF3B1-associated abnormal splicing.
We next sought to identify pathogenic splicing alterations asso-
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Fig. 7 Mutant SF3B1-associated alternative 3′ splice sites. a, b Mutant SF3B1-associated alternative 3′ splice sites in ABCB7 (a) and PPOX (b). RNA-seq
coverage is shown for samples with mutated and wild-type SF3B1, as well as for those with and without CHX treatment only in a. The bottom ﬁgure in
a illustrates an RNA sequence, a spliced transcript, and the corresponding amino acids near the 3´ splice site of exon nine of ABCB7. c, d RT-PCR of the
differentially spliced sites of ABCB7 (c) and PPOX (d). RT-PCR was performed for primary MDS samples and CRISPR cell lines with or without the
SF3B1K700E mutation. Clones #1 to #3 carried a heterozygous SF3B1K700E allele, while clones #4 to #6 had only wild-type alleles. Samples without reverse
transcription (RT) were used as a negative control. Samples treated with CHX are also shown in c. Canonical and abnormal transcripts are indicated by blue
and red triangles, respectively. e Immunoblots of CRISPR cell lines with or without the SF3B1K700E mutation. Lysates were processed for immunoblotting
with antibodies against denoted proteins. f, g Relative protein levels of ABCB7 (f) and PPOX (g). The dot plots show protein levels in three independent
clones. Statistical signiﬁcance was determined by the unequal variance t-test; t-values were 6.9 (f) and 4.3 (g)
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were recapitulated in the CRISPR cell lines and displayed a
moderate to large effect: those with a mean PSI value that is
greater than a 2-fold increase compared to controls and was
greater than 10% in either primary samples or those treated with
CHX. These criteria were met in 250 of 3831 (6.5%) mutant
SF3B1-associated alterations.
SF3B1 mutation is associated with the MDS with ring
sideroblasts characterized by defects in heme biosynthesis and
iron accumulation in mitochondria29. Of note, three genes
involved in heme biosynthesis and iron metabolism showed
aberrant splicing in SF3B1-mutated patients: ABCB7, PPOX, and
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observed in erythroid cells, bone marrow CD34+ cells from eight
SF3B1-mutated patients and four unmutated ones were differ-
entiated in vitro into erythroid cells. RNA sequencing was
performed on cells recovered on day 7 and day 14, which roughly
corresponded to CD36+ intermediate erythroblasts and glyco-
phorin A+ mature erythrocytes, respectively30,31. SF3B1-asso-
ciated alternative 3′ splice sites, including those of ABCB7, PPOX,
and TMEM14C, were similarly observed in the cultured erythroid
cells both at day 7 and at day 14, indicating consistent effect
across different hematopoietic lineages (Supplementary Fig. 23).
ABCB7, which encodes a protein involved in the transport of
heme from the mitochondria to the cytosol, was markedly
downregulated in the SF3B1-mutated samples as previously
reported;11,32 abnormal splicing of this gene was barely detected
in the primary specimens, but became evident after CHX
treatment of the SF3B1-mutated samples (Fig. 7a). The aberrant
3′ splice site was located at 21 bp upstream from the authentic
junction, inserting a nucleotide sequence harboring a PTC
(Fig. 7a). PPOX, which encodes an enzyme of heme biosynthesis,
was another target of mutant SF3B1-associated misrecognition of
3′ splice sites that introduces a frameshift (Fig. 7b). The mutant
SF3B1-associated TMEM14C transcripts also had an alternative 3′
splice site located in the 5′-untranslated region (UTR), although
this neither altered the amino acid sequence nor affected gene
expression as evaluated by luciferase assay (Supplementary
Figs. 24 and 25). Collectively, SF3B1 mutation induces abnormal
splicing and downregulation of two genes related to heme
biosynthesis, ABCB7 and PPOX. The splicing abnormalities in
these genes were recapitulated in HEK293T cells carrying a
heterozygous SF3B1K700E allele introduced by CRISPR/Cas9-
mediated gene editing (Fig. 7c, d). Downregulation of ABCB7 and
PPOX was also conﬁrmed at the protein level (Fig. 7e–g).
The candidate functional targets of mutant SF3B1-associated
splicing also contained a number of cancer-related genes. Typical
examples included known or putative tumor suppressors, such as
NF1, DICER1, PML, PDS5A, MAP3K7, and PPP2R5A, in which
SF3B1 mutation resulted in usage of alternative 3′ splice sites
(Supplementary Fig. 26). The abnormal splicing in these genes
yielded truncated transcripts with a reduction of canonical
transcripts (Fig. 3c).
SRSF2-associated mis-splicing and its functional targets. SRSF2
is an exonic splicing enhancer that binds to a consensus SSNG
sequence (where "S" denotes C or G) with no clear preference for
a particular sequence within this motif33. SRSF2 P95 mutants
were reported to have an altered afﬁnity for this consensus
sequence: an increased afﬁnity for a CCNG motif with a
decreased afﬁnity for a GGNG motif10. This leads to an enhanced
inclusion of exons with a CCNG sequence and a skipping of those
with a GGNG sequence. We compared relative frequencies of
SSNG motifs between constitutively and differentially spliced
exons in SRSF2-mutated samples. In agreement with previous
reports10,16, the included exons showed enrichment of CCNG
and depletion of GGNG, and vice versa for the skipped exons
(Fig. 8a). We further examined the spatial distribution of SSNG
motifs within the differentially spliced exons. The relevant CCNG
and GGNG motifs were not uniformly distributed across the
entire sequence of the affected exons, but were more enriched in
their most 3′ quarter (Fig. 8b). This suggests that like SF3B1
mutants, SRSF2 mutants preferentially affect splicing at 3′ splice
sites rather than at 5′ splice sites.
No cancer-related genes showed SRSF2-associated splicing
alterations characterized by a PSI value greater that 10%, and a
more than 2-fold increase compared to controls. Despite the
modest effect of individual mutant SRSF2-associated events,
EZH2 had multiple truncating splicing alterations. EZH2 encodes
the catalytic component of the polycomb repressive complex 2,
which acts as a tumor suppressor and is characterized by
recurrent loss-of-function mutations in myeloid
malignancies34,35. SRSF2-mutated samples showed an increased
inclusion of a cryptic exon harboring a PTC between exons 9 and
10 of EZH2 (RefSeq NM_004456), as previously reported10. We
also identiﬁed an additional EZH2 exon (exon 11) that was more
frequently skipped in SRSF2-mutated samples, leading to a
premature termination (Fig. 8c–e). RT-PCR of exons 9–13 and
cloning of the entire coding region of EZH2 conﬁrmed the
presence of transcripts with either or both of the two alterations
(Supplementary Figs. 27 and 28). These two events cooperatively
contributed to downregulation of the authentic transcript of
EZH2 (Figs. 3d and 8f and Supplementary Fig. 27). The
functional relevance of this ﬁnding was supported by the
upregulation of the targets of polycomb repressive complex 2
in SRSF2-mutated CD34+ cells, compared to those from healthy
adults (Supplementary Fig. 29)36.
We also identiﬁed additional targets of mutant SRSF2-associated
splicing alterations that are potentially involved in the development
of myelodysplasia, including CASP8 and CDK10. Mutant SRSF2-
associated exon skipping generated a prematurely terminated
transcript (Supplementary Fig. 30), leading to a reduction of the
canonical transcripts of the affected genes (Fig. 3d). We found no
major target genes that were commonly affected by both mutant
SRSF2- and SF3B1-associated splicing alterations; none of the major
target genes of SF3B1 mutation were affected by mutant SRSF2-
associated alternative splicing and showed signiﬁcant reduction of
the canonical transcripts.
Fig. 8 Mutant SRSF2-associated Cassette Exons in EZH2. a, b Forest plots show relative frequencies of CCNG and GGNG motifs within the differentially
spliced exons in the SRSF2-mutated samples. Two panels show the exons that are more frequently included (n= 380) (a) and skipped (n= 645) (b) in the
SRSF2-mutated samples, respectively. Comparisons were made between the differentially spliced exons and constitutive ones (n= 72,002). Red and blue
dots indicate relative frequencies of CCNG and GGNG, respectively. Bars indicate 95% conﬁdence intervals. Relative frequencies are shown for exons
divided into four segments with equal lengths. c Two cassette exons in EZH2 associated with SRSF2 mutation. The left is alternative exon usage and the
right is exon skipping. Gray boxes indicate constitutive exons. Red and blue boxes denote exons with increased and decreased usage in the SRSF2-mutated
samples, respectively. d PSI values of the cryptic exon between exons 9 and 10 of EZH2. BMMNC samples with different SF mutation status are plotted
separately. The middle line in each box corresponds to the median; the lower and upper boundaries of the box indicate ﬁrst and third quartiles, respectively.
The whiskers represent the 1.5-fold interquartile range or the maximum/minimum data point within the range. *** indicates Bonferroni adjusted P value <
0.001; **, adjusted P value < 0.01; *, adjusted P value < 0.05. e PSI values of exon 11 of EZH2. SRSF2-mutated samples and those without SF mutations are
plotted separately for BMMNCs and CD34+ cells. The number of samples in each group is shown in Fig. 1c. f mRNA levels of EZH2 isoforms compared
between the SRSF2-mutated samples and those without SRSF2 and EZH2 alterations. One sample with both SRSF2 and EZH2 mutations were removed from
this analysis. Normal transcripts are those from an EZH2 isoform without SRSF2-associated alterations in exon usage. Truncated transcripts are those from
EZH2 isoforms with at least one SRSF2-associated altered exon usage. Levels of normal transcripts were compared using the Mann–Whitney U test. W-
values were 340 in CD34+ cells and 630 in BMMNCs
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U2AF1-associated mis-splicing in cancer-related genes. Finally,
we sought to identify mutant U2AF1-associated splicing altera-
tions of pathogenic signiﬁcance. No cancer-related genes were
affected by 126 mis-splicing events strongly associated with
U2AF1 mutation (q-value <0.01 by t-test). However, EZH2 was
included among additional 237 splicing alterations associated
with U2AF1 mutation with q-value <0.05. Of note, this alteration
was the aforementioned cryptic exon that was associated with
SRSF2 mutation (cassette exon #1 in Fig. 8c). Inclusion of this
exon was increased in the samples with the U2AF1 S34 mutation,
but not in those with the Q157 mutation (Fig. 8d). We next
analyzed published transcriptome data of cell line experiments
expressing the U2AF1 S34F mutant or wild-type U2AF16. Exo-
genous expression of the U2AF1 S34F mutant actually enhanced
inclusion of the cryptic exon of EZH2 (Supplementary Fig. 31).
We next examined the sequence ﬂanking the 3′ splice site of the
EZH2 cryptic exon. The U2AF1 S34 mutant is shown to promote
recognition of C or A instead of T located three bases downstream
from the 3′ splice site (−3 position), while the Q157 mutant
enhances recognition of G instead of A at the +1 position9,21,22.
This altered pattern was conﬁrmed in the mutant U2AF1-associated
cassette exons in our analysis (Supplementary Fig. 32). The 3′ splice
site of the EZH2 cryptic exon has A at the −3 position, which is
preferentially bound by the U2AF1 S34 mutant protein (Fig. 8a). In
contrast, the+1 position of this cryptic exon was C, which does not
promote binding of the U2AF1 Q157 mutant (Fig. 8a). These
results were consistent with speciﬁc increase in the usage of the
EZH2 cryptic exon in the U2AF1 S34 mutant.
The association between the U2AF1 S34 mutation and the
splicing defect in EZH2 led us to hypothesized that the U2AF1
S34 mutation is mutually exclusive with EZH2 mutations. No
mutations or deletions of EZH2 were found in six patients with
the U2AF1 S34 mutation, but were found in 1 of 8 patients with
the Q157 mutation in our cohort. We further included two
cohorts in previous studies adding up to a total of 1325 patients
with myelodysplasia3,37. Although 13 of 66 patients with the
U2AF1 Q157 mutation had EZH2 mutations or deletions, no
genetic alteration of EZH2 was found in the U2AF1 S34-mutated
patients (n= 32), (P value= 0.008 by Fisher’s exact test). This
supports the pathogenic role of the splicing alteration of EZH2 in
the U2AF1 S34-mutated myelodysplasia.
Discussion
A high frequency of SF mutations is a distinctive feature of MDS
and related myeloid neoplasms, suggesting a critical pathogenic
role of deregulated RNA splicing. We performed a large-scale
RNA sequencing of primary samples with different SF mutations,
and investigated their impacts on RNA splicing and gene
expression in a genome-wide fashion. Effects of these mutations
on RNA splicing were further interrogated using NMD inhibition
experiments and CRISPR/Cas9-mediated gene editing.
Spliceosome mutations were associated with thousands of
alternative splicing events. As previously reported, 3′ splice site
alterations were predominant in SF3B1-mutated samples, whereas
SRSF2- and U2AF1-mutated samples were characterized by
alternative exon usage9–16,21,22. However, we identiﬁed small
reduction of intron-retaining isoforms as the most frequent
mutant SF3B1-associated abnormal splicing events. Recent stu-
dies indicate that many introns are “actively“ retained in mature
mRNAs38,39, some of which are stored in the nucleus, and then
spliced and recruited to the cytoplasm when increased protein
production is required, for example, during development and
erythropoiesis40,41. In contrast to these nuclear transcripts,
intron-retaining isoforms identiﬁed in our study were detected
even in the cytoplasm of SF3B1 wild-type control cells.
Differentially spliced introns were shorter and had a higher GC
content, which had been reported as features of introns that are
difﬁcult to splice42. These ﬁndings indicate that some introns are
physiologically retained in mRNAs, followed by export to the
cytoplasm. The vast majority of retained introns were conﬁrmed
to produce a PTC, which raises a possibility that activated NMD
might be the cause of reduction in intron-retaining transcripts.
However, the expression levels of these intron-retaining tran-
scripts were not inﬂuenced by CHX treatment, making this
possibility less likely. Decreased intron retention was more pro-
nounced in the cytoplasm compared with the nucleus. This
suggests an impaired export of intron-retaining transcripts from
the nucleus of SF3B1-mutated cells. In addition, intron-retaining
transcripts were also decreased in the nucleus of SF3B1-mutated
cells, indicating enhanced splicing of retained introns. These
results suggest an important role of SF3B1 in splicing regulation
and the export of intron-retaining transcripts.
High statistical power due to the large sample size allowed us to
identify precise targets of abnormal splicing associated with these
mutations. SF3B1 mutation induced aberrant 3′ splice site usage
in three genes related to heme biosynthesis and iron metabolism:
ABCB7, PPOX, and TMEM14C. Mis-splicing events in ABCB7
and TMEM14C were the same as those reported previously11–
13,43. In contrast to the splicing alteration of ABCB7 that intro-
duced a PTC, that of TMEM14C was located in the 5′-UTR and
did not have an effect on gene expression in a luciferase reporter
assay. A mutant SF3B1-associated splicing alteration of PPOX was
also reported previously, but it was differential exon usage, not an
alternative 3′ splice site identiﬁed in our study44. Misrecognition
of 3′ splice sites of PPOX introduced a frameshift and a PTC.
Taken together, the splicing alterations in ABCB7 and PPOX were
the candidates that might be responsible for ring sideroblast
formation in SF3B1-mutated myelodysplasia. We also identiﬁed
several cancer-related genes affected by SF3B1-associated abnor-
mal splicing: NF1, PDS5A, DICER1, and PML.
Little overlap had been found in alternatively spliced target
genes of the three most frequently mutated SFs45,46. We identiﬁed
EZH2 as a common target of splicing alterations associated with
SRSF2 and U2AF1 S34 mutations. The role of abnormal splicing
of EZH2 in SRSF2-mutated MDS was controversial in prior
studies10,16. Through extensive analysis of a large cohort, we
additionally found an exon skipping event associated with SRSF2
mutation, as well as conﬁrming enhanced inclusion of the pre-
viously reported cryptic exon10. We also found that one of the
two alterations was associated with U2AF1 S34 mutation. This
was supported by in vitro experiment data, the ﬂanking sequence
of the cassette exon that promotes binding of U2AF1 S34 mutant
protein, and the mutational landscape of myelodysplasia in which
EZH2 and U2AF1 S34 mutations were mutually exclusive.
Even with our large genetic study, splicing alterations were
rarely found in well-known driver genes of myeloid neoplasms. It
seems unlikely that the pathogenesis of SF-mutated myelodys-
plasia can be explained by a single mis-splicing event. Relative
lack of alterations in established driver genes rather supports the
previously proposed concept that multiple splicing alterations
may cooperatively contribute to the pathogenesis of MDS16. This
is paralleled by the molecular pathogenesis of the MDS with
deletion 5q, in which haploinsufﬁciency of a combination of key
genes mapping to the commonly deleted region results in a
speciﬁc myelodysplastic phenotype47. Further studies are war-
ranted to determine the biological effects of a single mis-splicing
event, as well as a combination of multiple alterations.
Methods
Patients and materials. These investigations were approved by the Ethics Com-
mittees of the Fondazione IRCCS Policlinico San Matteo, Pavia, of the Karolinska
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Institutet, Stockholm, and of Kyoto University, Kyoto. Written informed consent
was obtained from all patients. We enrolled 214 patients with myeloid neoplasms
with myelodysplasia followed at the Department of Hematology, University of
Pavia & Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy. Sample size was
determined to detect an absolute difference in PSI values of 10% with a two-tailed
alpha of 0.001 and power of 90%. Patients’ characteristics are summarized in
Supplementary Table 1. Diagnostic procedures were performed according to the
recommendations of the European LeukemiaNet48. The diagnostic criteria of the
WHO classiﬁcation of tumors of hematopoietic and lymphoid tissues were
adopted49,50. Quantitative enumeration of myeloblasts, ring sideroblasts and
monocytes and their precursors was performed using recently established con-
sensus criteria51,52. Human bone marrow mononuclear cells (BMMNCs; StemCell
Technologies, Vancouver, BC, Canada) and bone marrow CD34+ cells (Lonza,
Basel, Switzerland) of three healthy adults each were used as controls.
Targeted DNA sequencing. Genomic DNA was available for 211 of 214 patients
(99%). DNA was extracted from peripheral blood granulocytes (n= 111),
BMMNCs (n= 56), bone marrow polymorphonuclear cells (n= 43), or bone
marrow CD34+ cells (n= 1). Genomic DNA underwent whole-genome ampliﬁ-
cation in nine samples. Sequencing libraries were prepared from 200–1000 ng of
DNA. Target capture was performed using a SureSelect custom kit (Agilent
Technologies, Palo Alto, CA). RNA baits were designed to capture 89 known or
putative driver genes in MDS (MDS, Supplementary Table 2) using SureDesign
(Agilent Technologies). Target genes were selected based on the following criteria:
(1) mutational targets reported in the large genetic studies of MDS (n= 65)3–5,
(2) known driver genes in myeloid neoplasms (n= 10)3–5,53–63, (3) recurrently
mutated genes in our cohort of patients with myeloid neoplasms with myelodys-
plasia (n= 12)37, and (4) genes involved in the pathogenesis of anemia (n= 2).
Libraries were sequenced using the Illumina HiSeq 2000 or 2500 platform with
a standard 100-bp paired-end read protocol (Illumina, San Diego, CA). All
sequencing reads were aligned to the human reference genome (hg19) using BWA
version 0.7.10. Variants of >5% allele frequency were called using SAMtools after
all duplicated reads and low quality reads and bases were removed6. Called variants
were ﬁltered as in the previous paper and oncogenic variants were identiﬁed
(Supplementary Methods)4. Mutational hotspots of SF3B1 were deﬁned as amino
acid position 608–805, which corresponds to the 5th–9th HEAT repeats in the
previous report64. Expression of these variants was examined by RNA sequencing
as validation. A variant was regarded as validated if ≥2 variant allele reads were
expressed. For lowly expressed genes with <10 expression reads, a mutation was
conﬁrmed by the presence of ≥1 supporting reads or amplicon sequencing. Of all,
90% and 1.2% of the variants were validated by RNA sequencing and amplicon
sequencing, respectively.
Genomic copy number analysis was performed based on the sequencing depths
of the target regions. The depths were calculated from the weighted sum of the
fragments accounting for length and GC-biases during sequencing library
ampliﬁcation. The depths were compared to those of pooled controls. Genomic
copy number was estimated from the obtained depth ratios using circular binary
segmentation method with the DNAcopy package in R. Allelic imbalance was
assessed by the allele frequencies of the heterozygous SNPs covered by >50 reads.
RNA sequencing. RNA was extracted from BMMNCs and/or bone marrow CD34
+ cells from the patients. BMMNCs were separated from bone marrow samples by
standard density gradient centrifugation, and CD34+ cells were isolated using
MACS magnetic cell separation columns (Miltenyi Biotec, Bergisch Gladbach,
Germany) according to the manufacturer's recommendations65. Total RNA was
extracted with TRIzol reagent (Life Technologies, Carlsbad, CA) and treated with
DNase I (Qiagen, Hilden, Germany) using RNeasy Mini Kit (Qiagen) following the
recommendations of the manufacture. RNA integrity was examined with the
TapeStation (Agilent Technologies), and RNA samples with RNA integrity number
of >7 were sequenced. RNA sequencing was performed on BMMNCs (n= 165)
and CD34+ cells (n= 100) obtained from 214 patients, of whom 51 were analyzed
for both cell fractions (Fig. 1a). The RNA sequencing libraries were prepared from
polyA-selected RNA using the NEBNext Ultra RNA Library Prep kit for Illumina
(New England BioLabs, Ipswich, MA). Libraries were sequenced using the Illumina
HiSeq 2000 or 2500 platform with a standard 100-bp paired-end read protocol.
RNA sequencing analysis. The sequencing reads were aligned to the human
reference genome (hg19) using the RNA-seq uniﬁed mapper (RUM) version 2.0.4
and the transcripts were assembled using Cufﬂinks version 2.1.166,67. The assem-
blies were merged using Cuffmerge for all the CD34+ cell samples and for all the
BMMNC samples67. All genomic coordinates are based on GRCh37/hg19.
Alternative splicing analysis was performed using JuncBASE version 0.624.
JuncBASE was run with default settings to identify alternative splicing events and
calculate PSI values, which reﬂected fraction of reads showing alternative splicing.
Intron retention was assessed only for introns from the RefSeq database.
Alternative 5′ and 3′ sites were limited to those located within 500 nucleotides from
constitutive ones. Detection of coordinate cassette exon was omitted due to
computational burden. Differential splicing analysis was performed using
“compareSampleSets.py” of JuncBASE with the following parameters: –thresh
5 –mt_correction BH –which_test t-test –delta_thresh 0. All tests were two-sided
and equal variance was not assumed. Correction for multiple testing was done by
the Benjamini–Hochberg method, with cut-off q-values <0.01. Differences in PSI
values between samples with and without CHX treatment were tested by
Cochran–Mantel–Haenszel test. Inclusion of the two cassette exons of EZH2 in a
single RNA molecule was assessed from sequence fragments spanning the two
exon–exon junctions. Sequence logos were generated using WebLogo68.
Differential expression analysis was conducted using edgeR version 3.6.825. We
only analyzed genes expressed at >1 counts per million (CPM) in at least six
samples. Read counts derived from transcripts without truncating splicing
alterations were estimated from PSI values of the events with the highest fold
changes compared to the controls. Read counts were normalized using weighted
trimmed mean of M-values. For downstream analyses, normalized read counts
were converted to CPM and log2 transformed. Generalized linear models were used
to compare gene expression data among groups. Correction for multiple testing
was done by the Benjamini–Hochberg method. Genes with a false-discovery rate q-
value <0.01 were considered signiﬁcantly expressed. The R package GOseq version
1.18.0 was used to ﬁnd pathways enriched among differentially expressed genes69.
A gene set of the polycomb repressive complex 2 targets was adopted from the
previous report (Supplementary Methods)36. Enrichment scores were calculated
based on signal-to-noise ratio to depict running sum plots of the scores70.
CRISPR guide RNA vector construction and clone isolation. The human SF3B1
CRISPR guide RNA (gRNA) (5′-TGGATGAGCAGCAGAAAGTTcgg-3´) was
designed using the CRISPR design tool (http://crispr.mit.edu) and cloned into the
pSpCas9(BB)-2A-GFP (PX458; Addgene) vector. The 100-nt single-stranded oli-
godeoxynucleotide (ssODN) repair templates (Invitrogen) were designed with the
ﬂanking sequences centered on the predicted CRISPR/Cas9 cleavage site that
contained CRISPR/Cas-blocking mutations with or without SF3B1 K700E muta-
tion. CRISPR/Cas-blocking synonymous mutation was selected based on codon-
usage of human SF3B1 by changing the arginine codon to another codon already
used in the same mRNA. SF3B1 gRNA vector along with either wild type (5′-TA
GTTAAAACCTGTGTTTGGTTTTGTAGGTCTTGTGGATGAGCAGCAGA
AAGTTCGTACCATCAGTGCTTTGGCCATTGCTGCCTTGGCTGAAGCAGC
AA-3´) or K700E mutant (5′-TAGTTAAAACCTGTGTTTGGTTTTGTAG
GTCTTGTGGATGAGCAGCAGGAAGTTCGTACCATCAGTGCTTTGGCC
ATTGCTGCCTTGGCTGAAGCAGCAA-3´) ssODN was electroporated into
HEK293T cells using the NEON transfection system (Invitrogen). HEK293T cells
were obtained from the RIKEN Cell Bank. Cell lines were authenticated by short
tandem repeat DNA proﬁling and routinely tested for mycoplasma infection. After
24 h, cells were sorted for expression of GFP using the BD FACSAria III cell sorter
(BD Biosciences). The sorted cells were plated on 96-well plates for single-clone
isolation. Positive single clones were selected and conﬁrmed by PCR ampliﬁcation
(forward primer: 5′-GAGGTACACACACAGCCTGTC-3′; reverse primer: 5′-CA
AGAAAGCAGCCAAACCCTAT-3′) and sequencing.
Off-target analysis. Gene edited HEK293T cell lines were tested for off-target
editing events predicted by the Zhang laboratory CRISPR design tool (http://crispr.
mit.edu) and the COSMID (http://crispr.bme.gatech.edu). The top ﬁve non-
overlapping predicted off-target sites from each tool were examined (Supplemen-
tary Table 4). The region surrounding each off-target site was PCR-ampliﬁed,
sequenced and conﬁrmed not to have off-target mutations.
RT-PCR. Total RNA was isolated with the RNeasy Mini Kit (Qiagen). Cytoplasmic
and nuclear RNA were extracted with the cytoplasmic and nuclear RNA pur-
iﬁcation kit (Norgen Biotek Corp., Thorold, Canada). RNA was reverse-transcribed
using ReverTra Ace (Toyobo, Osaka, Japan) according to the manufacturer’s
instructions. Alternative spliced regions of ABCB7, PPOX, EZH2, RFNG, RECQL4,
NDOR1, AP1G2, and PIEZO1 cDNA were ampliﬁed. PCR products were run on a
4% agarose gel or a 10% or 15% polyacrylamide gel (BioRad, Hercules, CA).
Uncropped gel images are shown in Supplementary Figs. 33 and 34. Images were
minimally level adjusted using Adobe Photoshop Elements version 13. The relative
intensity of each band was measured using ImageJ software (National Institute of
Health, Bethesda, MD). Primer sequences used in RT-PCR are listed in Supple-
mentary Table 5.
The entire coding region of EZH2 was also PCR ampliﬁed from cDNA obtained
from a patient with SRSF2 mutation and SRSF2 wild-type one. PCR was performed
using the primes listed in Supplementary Table 5. Isolated clones were then cloned
into pUC19, followed by capillary sequencing.
qRT-PCR reactions were performed with Roche LightCycler 480 SYBR Green I
Master as recommended by the manufacturer, and run on a LightCycler 480
(Roche). Ct values were normalized to the housekeeping gene β-actin. Primer
sequences used in qRT-PCR are listed in Supplementary Table 5.
Immunoblots. HEK293T cells were lysed in RIPA buffer (Santa Cruz Bio-
technology, Inc., Santa Cruz, CA), subjected to SDS-PAGE and transferred to a
polyvinylidene diﬂuoride membrane (Millipore, Darmstadt, Germany). Each blot
was incubated with the antibodies described in Supplementary Table 6, and signals
were detected with Immobilon Western Chemiluminescent HRP Substrate
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(Millipore). Uncropped images are shown in Supplementary Fig. 35. Images were
minimally level adjusted using Adobe Photoshop Elements version 13.
Erythroid cell culture. Erythroid cells were obtained in vitro from selected CD34+
cells. Following separation, CD34+ cells were cultured (0.5–1 × 105/mL) for
14 days in Iscove’s medium supplemented with 15% BIT9500 serum substitute
(Stem Cell Technologies, Tebu-Bio, Milan, Italy), 100 U/ml penicillin-streptomycin
and 2 mM L-glutamin, rh-IL-3 (10 ng/mL) (PeproTech House, Tebu-Bio, Milan
Italy), rh-IL-6 (10 ng/mL) (PeproTech House), rh-SCF (25 ng/ml) (PeproTech
House). Epo (2 iu/ml) was added to the medium at day 7, and fresh medium
supplemented as above (plus Epo) was added at day 9 and 11. Cells recovered on
day 7 and day 14 were suspended in TRIzol Reagent (Life Technologies) and
subjected to RNA sequencing.
Inhibition of nonsense-mediated mRNA decay by CHX. CHX, a translation
elongation inhibitor, was used to block nonsense-mediated mRNA decay and to
identify abnormal transcripts. Optimal concentration and exposure were deter-
mined after treatment with CHX (Sigma-Aldrich, Saint Louis, MO, USA) at
increasing doses of 10, 20, 40, and 70 μg/mL for 1, 2, or 12 h. BMMNCs and
CD34+ cells were seeded in complete medium (IMDM supplemented with 15%
BIT9500, 100 U/ml penicillin-streptomycin, 2 mM L-glutamin, 10 ng/mL rh-IL-3,
10 ng/mL rh-IL-6, 25ng/ml rh-SCF) at 0.1 × 106 cells/mL density in humidiﬁed
atmosphere of 5% CO2 at 37 °C for 2 h. After incubation, cells were cultured at the
ﬁnal concentration of 70 μg/mL CHX for 2 h. Cell viability was assessed by ﬂow
cytometry using 7-amino-actinomycin D. HEK293T cells were treated with CHX at
the ﬁnal concentration of 100 μg/mL for 3 h. Total RNA was isolated using TRIzol
Reagent (Life Technologies) and subjected to mRNA isoforms expression analysis.
5′-rapid ampliﬁcation of cDNA end. 5′-rapid ampliﬁcation of cDNA end (RACE)
was performed using SMARTer RACE 5′/3′ kit (Takara) to obtain the sequence of
TMEM14C 5′-UTR. Primer sequences used in 5′-RACE are listed in Supplemen-
tary Table 5. The products with and without the mutant SF3B1-associated splicing
alteration were cloned into pGL3-Basic vector (Promega) directly upstream of the
coding region of ﬁreﬂy luciferase for use in subsequent luciferase assays.
Luciferase assay. pGL3-Basic vector with TMEM14C 5′-UTR with or without the
mutant SF3B1-associated splicing alteration, and empty pGL3-Basic construct were
transfected into HEK293T cells. HEK293T cells were collected 24 h after trans-
fection and assayed for luciferase activity using the Dual-Luciferase Reporter Assay
System (Promega) and a Multilabel Plate Reader ARVO X5 (PerkinElmer, Wal-
tham, MA). Fireﬂy luciferase activity was normalized against Renilla luciferase
activity (phRL-TK vector, Promega) in each sample and is presented relative to the
activity in mock-transfected cells.
Statistical analysis. Numerical variables were summarized by median and range;
categorical variable were described with count and relative frequency (%) of sub-
jects in each category. Comparison of numerical variables between groups was
carried out using a nonparametric approach (Mann–Whitney U test or Kruskall
Wallis ANOVA). Comparison of the distribution of categorical variables in dif-
ferent groups was performed with the Fisher exact test.
Data availability
Genome data that support the ﬁndings of this study have been deposited at the European
Genome-phenome Archive, which is hosted at the EBI, under accession number
EGAS00001002346. All other remaining data are available within the Article and Sup-
plementary Files, or available from the authors upon request.
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